The βAPP717 Alzheimer mutation increases the percentage of plasma amyloid-β protein ending at Aβ42(43)

T. Kosaka, M. Imagawa, K. Seki, H. Arai, H. Sasaki, S. Tsuji, A. Asami-Odaka, T. Fukushima, K. Imai, Takeshi Iwatsubo

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

We measured plasma levels of amyloid β protein (Aβ) ending at positions 40 (Aβ40) and 42(43) [Aβ42(43)] in six carriers of βAPP717 (Val to Ile) mutation linked to familial Alzheimer's disease (FAD) as well as in patients with sporadic AD (sAD) and controls. The percentage and the level of Aβ42(43) were significantly higher in carriers of βAPP717 mutation relative to sAD, whereas Aβ40 levels were decreased. In contrast, Aβ levels and ratios were at similar levels in sAD, regardless of the stage of the disease, compared with non-AD neurologic disease controls and nondemented control individuals. These results suggest that the reported increase in the percentage of Aβ42(43) secretion in transfected cells with βAPP717 mutant genes actually takes place in the bodies of carriers of βAPP717 mutation, and that plasma Aβ could be used as an indicator of the alterations of βAPP/Aβ metabolism in subtypes of AD.

Original languageEnglish
Pages (from-to)741-745
Number of pages5
JournalNeurology
Volume48
Issue number3
DOIs
Publication statusPublished - 1997 Mar

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'The βAPP717 Alzheimer mutation increases the percentage of plasma amyloid-β protein ending at Aβ42(43)'. Together they form a unique fingerprint.

  • Cite this

    Kosaka, T., Imagawa, M., Seki, K., Arai, H., Sasaki, H., Tsuji, S., Asami-Odaka, A., Fukushima, T., Imai, K., & Iwatsubo, T. (1997). The βAPP717 Alzheimer mutation increases the percentage of plasma amyloid-β protein ending at Aβ42(43). Neurology, 48(3), 741-745. https://doi.org/10.1212/WNL.48.3.741